If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
The focus is on wellness and personal care products
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
Subscribe To Our Newsletter & Stay Updated
